Jeffrey La Rosa

Stock Analyst at Leerink Partners

(0.08)
# 4,417
Out of 5,044 analysts
4
Total ratings
25%
Success rate
-37.72%
Average return

Stocks Rated by Jeffrey La Rosa

Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79$91
Current: $29.76
Upside: +205.78%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $3.40
Upside: +252.94%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110$112
Current: $87.03
Upside: +28.69%